Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation & Amortization (2016 - 2022)

Historic Accumulated Depreciation & Amortization for Spyre Therapeutics (SYRE) over the last 9 years, with Q4 2023 value amounting to $744000.0.

  • Spyre Therapeutics' Accumulated Depreciation & Amortization fell 5252.07% to $744000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $744000.0, marking a year-over-year decrease of 5252.07%. This contributed to the annual value of $744000.0 for FY2023, which is 5252.07% down from last year.
  • According to the latest figures from Q4 2023, Spyre Therapeutics' Accumulated Depreciation & Amortization is $744000.0, which was down 5252.07% from $1.6 million recorded in Q4 2022.
  • In the past 5 years, Spyre Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $2.0 million in Q4 2020 and a low of $744000.0 during Q4 2023
  • For the 5-year period, Spyre Therapeutics' Accumulated Depreciation & Amortization averaged around $1.4 million, with its median value being $1.6 million (2022).
  • As far as peak fluctuations go, Spyre Therapeutics' Accumulated Depreciation & Amortization surged by 8796.21% in 2020, and later crashed by 5252.07% in 2023.
  • Spyre Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $1.1 million in 2019, then soared by 87.96% to $2.0 million in 2020, then decreased by 20.52% to $1.6 million in 2021, then dropped by 0.57% to $1.6 million in 2022, then plummeted by 52.52% to $744000.0 in 2023.
  • Its Accumulated Depreciation & Amortization stands at $744000.0 for Q4 2023, versus $1.6 million for Q4 2022 and $1.6 million for Q4 2021.